Interpace Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Interpace Biosciences, Inc.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.
Merck KGAA and Pfizer teamed up in an $850 million immunotherapy partnership; after fighting off Valeant’s efforts for months, Allergan ended up agreeing to a $65 billion acquisition by Actavis. Both biopharma and device financing were up vs. the previous month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2014.
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
Laboratory Testing Services
- Anatomical Pathology
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Interpace Diagnostics Group, Inc.
- PDI, Inc.
- RedPath Integrated Pathology